CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aytu Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aytu Biopharma Inc
7900 E. Union Avenue, Suite 920
Phone: (720) 437-6580p:720 437-6580 DENVER, CO  80237  United States Ticker: AYTUAYTU

Business Summary
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8200 Educational services

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Joshua R.Disbrow 48 1/27/2016 4/16/2015
Chief Financial Officer, Treasurer, Company Secretary Mark K.Oki 54 5/5/2022 1/17/2022
Chief Commercial Officer GregPyszczymuka 44 1/1/2022 1/1/2022
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Innovus Pharmaceuticals, Inc. 8845 Rehco Road San Diego CA United States
Vyrix Pharmaceuticals Inc Suite 925, 5445 DTC Parkway GREENWOOD VILLAGE CO United States
Semprae Laboratories, Inc. 160 Pehle Ave Saddle Brook NJ United States
Neos Therapeutics Inc 2940 N State Highway 360 Ste 400 Grand Prairie TX United States

Business Names
Business Name
AYTU
Aytu Therapeutics, LLC
AYTUD
6 additional Business Names available in full report.

General Information
Number of Employees: 150 (As of 6/30/2023)
Outstanding Shares: 5,567,597 (As of 2/1/2024)
Shareholders: 190
Stock Exchange: NASD
Federal Tax Id: 470883144
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024